Robert S Stern1. 1. Department of Dermatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. rstern@bidmc.harvard.edu
Abstract
OBJECTIVE: To assess the risk of lymphoma in patients with psoriasis. DESIGN: Prospective cohort study that spans 30 years and a systematic review of the literature. SETTING: Sixteen university medical centers. PATIENTS: A total of 1380 patients with psoriasis who were initially treated with psoralen-UV-A (PUVA) from 1975 through 1976 and who underwent periodic interviews and physician examinations irrespective of their use of any treatment. MAIN OUTCOME MEASURE: Incidence of lymphoma relative to that expected in the general US population (original primary end point of the study). RESULTS: The incidence of lymphoma in patients who received PUVA and were not exposed to high levels of methotrexate was comparable to that expected in the general population (incidence rate ratio, 0.85; 95% confidence interval, 0.37-1.67) but was elevated among those exposed to high levels of methotrexate (> or =36 months) (incidence rate ratio, 4.39; 95% confidence interval, 1.59-12.06). CONCLUSION: Unless exposed to high levels of methotrexate, the risk of lymphoma among members of the PUVA Follow-up Study was comparable to that observed in the general population.
OBJECTIVE: To assess the risk of lymphoma in patients with psoriasis. DESIGN: Prospective cohort study that spans 30 years and a systematic review of the literature. SETTING: Sixteen university medical centers. PATIENTS: A total of 1380 patients with psoriasis who were initially treated with psoralen-UV-A (PUVA) from 1975 through 1976 and who underwent periodic interviews and physician examinations irrespective of their use of any treatment. MAIN OUTCOME MEASURE: Incidence of lymphoma relative to that expected in the general US population (original primary end point of the study). RESULTS: The incidence of lymphoma in patients who received PUVA and were not exposed to high levels of methotrexate was comparable to that expected in the general population (incidence rate ratio, 0.85; 95% confidence interval, 0.37-1.67) but was elevated among those exposed to high levels of methotrexate (> or =36 months) (incidence rate ratio, 4.39; 95% confidence interval, 1.59-12.06). CONCLUSION: Unless exposed to high levels of methotrexate, the risk of lymphoma among members of the PUVA Follow-up Study was comparable to that observed in the general population.
Authors: Anna E Prizment; Alvaro Alonso; Aaron R Folsom; Rehana L Ahmed; Beth A Virnig; Erin M Warshaw; Kristin E Anderson Journal: Cancer Causes Control Date: 2011-05-07 Impact factor: 2.506
Authors: Lorenzo Nosotti; Andrea Baiocchini; Claudio Bonifati; Ubaldo Visco-Comandini; Concetta Mirisola; Franca Del Nonno Journal: World J Hepatol Date: 2015-04-18
Authors: Rachael L Gross; Julie S Schwartzman-Morris; Michael Krathen; George Reed; Hong Chang; Katherine C Saunders; Mark C Fisher; Jeffrey D Greenberg; Chaim Putterman; Philip J Mease; Alice B Gottlieb; Joel M Kremer; Anna Broder Journal: Arthritis Rheumatol Date: 2014-06 Impact factor: 10.995
Authors: Alexa B Kimball; Dafna Gladman; Joel M Gelfand; Kenneth Gordon; Elizabeth J Horn; Neil J Korman; Gretchen Korver; Gerald G Krueger; Bruce E Strober; Mark G Lebwohl Journal: J Am Acad Dermatol Date: 2008-03-04 Impact factor: 11.527